Objective Construction of a neuroblastoma (NB) prognostic predictive model based on pyroptosis-related genes (PRGs) to improve individualized management of NB patients. Methods The NB cohort GSE49711 was obtained from the Gene Expression Omnibus (GEO) database, and a total of 498 patients were enrolled into the study, which were randomized into a training set and a test set at a ratio of 1:1, with 250 patients in the training set and 248 patients in the test set. A risk prediction model was constructed using the training set, and the GSE49711 cohort and test set were used as internal validation to verify the reliability of the model. Independent predictors associated with prognosis were screened using univariate and multivariate COX regression analyses, and risk score models were constructed. Single-cell gene set enrichment analysis (ssGSEA) was used to assess the relationship between PRGs and the tumor immune microenvironment. Nomograms were constructed to extend the clinical usability of the model and the reliability of the model was verified using ROC curves and calibration curves. Protein interaction networks of risk genes were mapped using the String database, and the expression of PRGs in NB cell lines was staged using the CCLE database. Results A prognostic model was first developed with the training set: the risk score formula was (− 0.30 × GSDMB) + (− 0.46 × IL-18) + (− 0.21 × NLRP3) + (0.56 × AIM2). Patients were categorized into high- and low-risk groups based on the median risk score value. Survival analysis showed that NB patients in the high-risk group had a significantly lower survival rate than those in the low-risk group (P < 0.001). In both the GSE49711 overall cohort and the test cohort, survival analyses showed that patients in the high-risk group had significantly lower survival than those in the low-risk group (P < 0.001). Single-cell gene set enrichment analysis was used to assess the relationship between PRGs and the tumor immune microenvironment. Time-dependent ROC curves assessed the predictive performance of the nomogram in 5-, 7.5-, and 10-year survival with areas under the curve (AUC) of 0.843, 0.802 and 0.797, respectively. The calibration curves show good clinical predictive performance for nomograms. Conclusion The results suggest that PRGs may serve as a novel prognostic marker for NB patients to provide new immunotherapeutic targets for the clinical treatment of NB patients.
Background Neuroblastoma (NB) is one of the most common extracranial malignancies in central nervous system, threatening children’s health. It is an embryonic neural crest cell-derived pediatric solid tumor, usually resulting in tumors in the adrenal glands or the sympathetic ganglia. The clinical presentation can be quite heterogeneous, ranging from asymptomatic incidental tumors to widespread metastases with systemic manifestations. While children diagnosed with clinically stable NB can be completely cured, those with high-risk NB have a poor prognosis despite combination therapy strategies. In order to assess the prognosis of NB patients, sensitive biomarkers are worthy of in-depth study.Methods We obtain raw data from TARGET and GEO databases. Next, the role of ferroptosis death-related genes (FRGs) as a prognostic biomarker for NB patients was discussed. And Pearson correlation analysis and Cox regression analysis were used to select FRGs related to prognosis.Results Five genes were selected to construct a prognostic prediction model in the TARGET cohort. The risk score was calculated based on 5 FRGs. And according to the median value of risk score, patients were divided into low-risk group and high-risk group. The high-risk group has relatively higher abundance among immune cells. The expression of immuno-oncology target is up-regulated in patients with high-risk scores. In addition, the high-risk group is more related to oxidative phosphorylation and MTORC1 signaling. And to assess the overall survival (OS) of NB patients, a nomogram (based on MKI, COG risk group and risk score) was also established.Conclusion FRGs can be used as sensitive biomarkers to predict the prognosis of NB patients, and can be used in clinical immunotherapy and targeted therapy.
Hepatoblastoma (HB) is the most common malignant tumor in children under 5 years old, but its pathogenesis remains unclear. Nur77 has been reported to be an important regulator for cancer progression in various cancer types. This study found that Nur77 was downregulated in HB tumors, compared with paracancer tissue. Knockout or overexpression of Nur77 in HB tumor cell line HepG2 and HuH6 could significantly enhance or inhibit the proliferation, migration and invasion of tumor cells both in vitro and in vivo. Further studies illustrated that Nur77 regulated the proliferation of tumor cells by affecting the expression of β-catenin. Nur77 agonist Cns-A effectively enhanced the therapeutic effect of cisplatin on HB tumors both in vitro and in vivo. This study proved that Nur77 could act as a tumor suppressor gene in HB tumors, providing a new direction for improving the clinical responses of HB.
Objective Construction of a NB prognostic model based on pyroptosis-related genes (PRGs) to improve individualized management of NB patients. Methods The GEO-NB cohort from the Gene Expression Omnibus (GEO) database was obtained and randomized into training and test groups, and finally 498 cases were included for analysis. The model was constructed using the training set, and the test set data were used as the validation set to screen for prognostically significant variables using the Log-rank test, and then the optimal multigene prognostic model was built using LASSO-Cox regression analysis. The accuracy of the prognostic model was assessed using ROC curves, column plots, and calibration curves. Results A prognostic model was first developed with the training set: the risk score formula was (-0.30 × GSDMB) + (-0.46 × IL18) + (-0.21 × NLRP3) - (0.56 × AIM2). Patients were categorized into high- and low-risk groups based on the median risk score value. Survival analysis showed that NB patients in the high-risk group had a significantly lower survival rate than those in the low-risk group (P < 0.001). The area under curve (AUC) of the time-dependent ROC curve predicting 5-, 7.5-, and 10-year survival was 0.843, 0.802, and 0.797, respectively. In the GEO test cohort, patients in the high-risk group had worse prognostic patients compared with those in the low-risk group (P=0.035). The calibration curve of the alignment diagram show that the alignment diagram has good clinical value. Conclusion A prognostic model for predicting survival in NB patients was constructed based on PRGs, and the accuracy of the model was validated in an overall cohort and test cohort.
Atypical teratoid/rhabdoid tumor (AT/RT) is a highly aggressive embryonal central nervous system tumor that predominantly affects young children. Despite p